|Keryx Biopharmaceuticals Initiates Phase 3 Registration Program Of Zerenex (ferric Citrate) For The Treatment Of Patients With Hyperphosphatemia|
|Scritto da Urology/Nephrology News From Medical News Today|
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the initiation of its short-term Phase 3 study of Zerenex? (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis...
Fonte: Urology/Nephrology News From Medical News Today